Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 6/20 | 0.43 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.39 |
| ▸ | TTK | P33981 | 7/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22122856 | 1.00 | PTK2 (0.43) | PTK2PTK6TTKAURKBJAK2 | |
| Hydrochloric Acid SCHEMBL30171580 | 0.99 | PTK2 (0.43) | PTK2PTK6TTKAURKBJAK2 | |
| Hydrochloric Acid SCHEMBL30172045 | 0.99 | PTK2 (0.43) | PTK2PTK6TTKAURKBJAK2 | |
| SCHEMBL22123264 | 0.96 | PTK2 (0.46) | PTK2PTK6TTKAURKBMAPKAPK5 | |
| SCHEMBL30385433 | 0.94 | PTK2 (0.42) | PTK2PTK6TTKAURKBJAK2 | |
| Formic Acid SCHEMBL30171777 | 0.93 | PTK2 (0.44) | PTK2PTK6TTKAURKBHTR4 | |
| SCHEMBL22122871 | 0.93 | PTK2 (0.39) | PTK2PTK6TTKAURKBJAK2 | |
| SCHEMBL30171895 | 0.93 | PTK2 (0.43) | PTK2PTK6TTKAURKBJAK2 | |
| SCHEMBL22139108 | 0.93 | PTK2 (0.43) | PTK2PTK6TTKAURKBJAK2 | |
| SCHEMBL24112378 | 0.93 | PTK2 (0.39) | PTK2PTK6TTKAURKBJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3898631-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | PTK2 4090/4885PTK6 2211/4885TTK 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.